Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350345 | 0.82 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL12237083 | 0.82 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL10109154 | 0.71 | THRB (0.41) | ALDH1A1SMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL10020569 | 0.68 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL13267564 | 0.68 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24328680 | 0.67 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL12183703 | 0.67 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13078359 | 0.67 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL12138460 | 0.66 | — | — | |
| SCHEMBL19368104 | 0.64 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | ALDH1A1 4129/4885SMN1; SMN2 1307/4885LMNA 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.